Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?Article Published on 2023-04-012023-07-11 Journal: British Journal of Haematology [Category] COVID19(2023년), [키워드] Allogeneic COVID-19 Hematopoietic cell transplantation SARS-CoV-2 transplantation vaccination [DOI] 10.1111/bjh.18591 PMC 바로가기
Human herpesvirus-6 in hematopoietic stem cell transplant recipients: a prospective cohort study in Egyptarticle Published on 2023-02-042024-09-05 Journal: Virology Journal [Category] update2024, [키워드] Allogeneic autologous hematopoietic stem cell transplantation HHV-6 reactivation HSCT human herpesvirus 6 [DOI] 10.1186/s12985-023-01980-w PMC 바로가기 [Article Type] article
Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysisArticle Published on 2022-10-012022-11-15 Journal: Transplantation [Category] 진단, [키워드] 95% CI 95% confidence interval age Allogeneic calcineurin Cell combating Comorbidity coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccines dose Effects Factor General population healthy control higher risk humoral Immunocompromised Immunosuppressant immunosuppressive inclusion criteria increased risk inhibitor inhibitors mammalian medication Meta-analysis much lower Organ transplant outcome pandemic performed pooled rate Population Rapamycin receiving recipient recipients regimen response review risk factor second dose Seroconversion seroconversion failure Steroids systematic review the vaccine Transplant Vaccine vaccine response [DOI] 10.1097/TP.0000000000004256 PMC 바로가기
Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorryArticle Published on 2022-10-012022-11-15 Journal: Bone marrow transplantation [Category] 바이오마커, [키워드] Allogeneic Analysis attribute CD3 CD34 Cell cells CFU-GM Characteristics Clinical outcome Collection Contamination correlated correlation COVID-19 pandemic cryopreservation group hematopoietic progenitor cell indicated investigated nucleated cell pandemic Patient Peripheral blood prevented Quality control raised Red cell remained Safe shown statistically significant thawing Univariate analysis variable Volume [DOI] 10.1038/s41409-022-01750-2 PMC 바로가기
Reduced Immune Response and Neutralizing Antibody Activity to the SARS-CoV-2 Vaccination in Patients with a History of Solid Organ TransplantArticle Published on 2022-09-012022-11-15 Journal: Laboratory medicine [Category] SARS, 변종, 진단, 치료기술, [키워드] activity Allogeneic antibodies antibody booster Cell Control controls COVID-19 healthcare worker history immune immune response in vitro monoclonal mounted Neutralizing activity neutralizing antibody nucleocapsid organ Patient patients plasma positive produced reduced Remnant response Sample SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 vaccination Solid solid organ solid organ transplant Spike protein the antibody the SARS-CoV-2 Transplant vaccination variant virus was obtained wild type [DOI] 10.1093/labmed/lmac038 PMC 바로가기
Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell TransplantationArticle Published on 2022-09-012022-11-16 Journal: Transplantation and cellular therapy [Category] COVID19(2023년), SARS, 치료기술, [키워드] age Allogeneic allogeneic transplantation antibody Antibody Response average binding antibody unit Blood donors BNT162b2 chronic GVHD CORD COVID-19 detectable Donor dose Efficacy Graft-versus-host disease GVHD in vivo independent predictor initial involved JNJ-78436735 Johnson & Johnson less Lymphocyte count lymphocyte counts Moderna mRNA-1273 multivariable analysis Patient Predictive Prophylaxis question recipient recipients respond response robust SARS-CoV-2 spike protein SARS-CoV-2 vaccination Serologic response STEM stem cell Stem cell transplantation T cell depletion T-cell T-cell Depletion Transplant transplantation transplants umbilical cord blood vaccination Vaccine [DOI] 10.1016/j.jtct.2022.06.012 PMC 바로가기
Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major Research Published on 2022-08-242022-10-05 Journal: Bone marrow transplantation [Category] 바이오마커, [키워드] Affect affected age Allogeneic cell transplantation concerning cumulative cured Diabetes Mellitus diagnosed disorders Effect evaluated female Fertility Follow-up gonadal growth HCT hematological incidence Infection kidney liver long-term survival lung majority male median Mortality Neonate Neonates neurologic obesity osteoarticular Patient patients who survived performance status preserved Psychiatric Retrospective study solid cancer SSC survival thalassemia Thyroid [DOI] 10.1038/s41409-022-01786-4 [Article Type] Research
Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia Correspondence Published on 2022-08-202022-10-05 Journal: Bone marrow transplantation [Category] 변종, [키워드] Allogeneic DDX41 leukemia mutated Patient syndrome [DOI] 10.1038/s41409-022-01776-6 [Article Type] Correspondence
Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients동종 조혈모세포 이식 환자에서 SARS-CoV-2 BNT162b2 백신 접종에 대한 체액 및 세포 반응Article Published on 2022-08-052022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Allogeneic anti-S IgG anti-S IgG levels assays baseline BNT162b2 both group both groups CD4 cellular cellular response Cohort correlation defined detectable doses ELISpot assay evaluated exhibited FIVE flow cytometry group humoral Humoral and cellular responses Humoral response IFNγ IgG level Immunosuppressive treatment lymphocyte mRNA vaccination Neutralizing antibodies neutralizing antibody not significantly different Patient percentage Previous studies previous study proliferation proliferative prospectively studied recipient Responder SARS-CoV-2 SARS-CoV-2 BNT162b2 seroconverted serological Stem cell transplantation T cell T cells Two patient vaccination Vaccine [DOI] 10.1016/j.vaccine.2022.07.006 PMC 바로가기 [Article Type] Article
Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 20192019년 코로나바이러스로 인한 급성호흡곤란증후군에 대한 중간엽 기질세포 치료Article Published on 2022-08-012022-09-12 Journal: Cytotherapy [Category] 진단, [키워드] 95% CI 95% confidence interval acute lung injury acute respiratory distress acute respiratory distress syndrome Allogeneic anti-inflammatory property ARDS C-reactive protein case sery cells clinical outcomes coronavirus disease COVID-19 COVID-19-associated ARDS declined discharged dose eligible follow-up period high mortality hospital Inflammatory cytokine intensive care Kidney injury less liver Lung disease mechanical ventilation mechanically ventilated median time Mesenchymal stromal cell Mesenchymal stromal cells moderate MSC MSCs nine Patient patients patients died remained Remestemcel-L requiring supplemental oxygen resulting Safe shown significantly stromal cell syndrome therapy treat treated were excluded [DOI] 10.1016/j.jcyt.2022.03.006 PMC 바로가기 [Article Type] Article